- Home
- ABTS vs SLGL Comparison
ABTS vs SLGL Comparison
Compare ABTS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- SLGL
- Stock Information
- Founded
- ABTS 2010
- SLGL 1997
- Country
- ABTS Hong Kong
- SLGL Israel
- Employees
- ABTS N/A
- SLGL N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- SLGL Health Care
- Exchange
- ABTS Nasdaq
- SLGL Nasdaq
- Market Cap
- ABTS 15.9M
- SLGL 17.0M
- IPO Year
- ABTS N/A
- SLGL 2018
- Fundamental
- Price
- ABTS $3.31
- SLGL $0.60
- Analyst Decision
- ABTS
- SLGL Strong Buy
- Analyst Count
- ABTS 0
- SLGL 2
- Target Price
- ABTS N/A
- SLGL $5.00
- AVG Volume (30 Days)
- ABTS 27.5K
- SLGL 42.7K
- Earning Date
- ABTS 12-31-2024
- SLGL 03-21-2025
- Dividend Yield
- ABTS N/A
- SLGL N/A
- EPS Growth
- ABTS N/A
- SLGL N/A
- EPS
- ABTS N/A
- SLGL N/A
- Revenue
- ABTS $5,343,888.00
- SLGL $11,707,000.00
- Revenue This Year
- ABTS N/A
- SLGL $772.97
- Revenue Next Year
- ABTS N/A
- SLGL N/A
- P/E Ratio
- ABTS N/A
- SLGL N/A
- Revenue Growth
- ABTS 3970.67
- SLGL 869.93
- 52 Week Low
- ABTS $0.25
- SLGL $0.33
- 52 Week High
- ABTS $4.19
- SLGL $1.65
- Technical
- Relative Strength Index (RSI)
- ABTS 80.04
- SLGL 44.43
- Support Level
- ABTS $3.07
- SLGL $0.55
- Resistance Level
- ABTS $3.74
- SLGL $0.66
- Average True Range (ATR)
- ABTS 0.20
- SLGL 0.07
- MACD
- ABTS 0.37
- SLGL 0.01
- Stochastic Oscillator
- ABTS 77.66
- SLGL 42.44
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.